Blog Posts in 2012
248 results found. Viewing page 1 of 10.
Go to page
Posted on Dec 20, 2012 By Arnold & Itkin
Pfizer Inc. has agreed to pay $55 million to resolve allegations that one of its subsidiaries, Wyeth LLC, illegally promoted the drug Protonix for uses that were not approved by the Food and Drug ...
Continue reading "Pfizer to Pay $55 Million to Settle Misbranding Case" »
Posted on Dec 19, 2012 By Arnold & Itkin
Chantix, Pfizer's quit smoking drug, has frequently come under fire for causing terrible side effects like depression and suicidal tendencies. Now, according to a new review conducted by the Food ...
Continue reading "Another Chantix Side Effect Comes to Light" »
Posted on Dec 10, 2012 By Arnold & Itkin LLP
The Food and Drug Administration (FDA) recalled the 32-mg dose of the anti-nausea drug Zofran on December 4 because of concerns that it might cause patients to experience cardiac problems. Zofran is ...
Continue reading "Nausea Drug Recalled over Cardiac Concerns" »
Posted on Nov 21, 2012 By Arnold & Itkin, LLP
GlaxoSmithKline (GSK) has agreed to pay $90 million to settle claims by 37 states and Washington D.C that the company illegally promoted its diabetes drug Avandia. The settlement resolves claims that ...
Continue reading "GSK Settles Avandia Claims for $90 Million" »
Posted on Nov 20, 2012 By Arnold & Itkin, LLP
Drug manufacturing giant Pfizer Inc has settled a class-action lawsuit with shareholders who were misled about risks associated with the antidepressant Pristiq. The cost to Pfizer will be a whopping ...
Continue reading "Pfizer Settles Pristiq Lawsuit for $67 Million" »
Posted on Nov 20, 2012 By Arnold & Itkin, LLP
Staff reviewers at the Food and Drug Administration (FDA) have questioned the safety of Novo Nordisk's diabetes drugs Tresiba and Ryzodeg, saying they increase the risk of cardiovascular death. An ...
Continue reading "FDA Questions Safety of Two Different Diabetes Drugs" »
Posted on Nov 19, 2012 By Arnold & Itkin, LLP
Fifty years ago, the anti-nausea drug Thalidomide was pulled from the market after countless babies were born with defects to mothers who took the medication during pregnancy. Now, for the first time, ...
Continue reading "Drug Maker Offers Apology for Birth Defects 50 Years Later" »
Posted on Nov 12, 2012 By Arnold & Itkin
Pristiq, or desvenlafaxine, is a commonly used drug for those who are suffering with depression. Those who struggle with depression not only are left feeling sad and unmotivated, but these emotions ...
Continue reading "Pristiq Class Action Suit Settled for $67.5 Million" »
Posted on Nov 9, 2012 By Arnold & Itkin LLP
The Food and Drug Administration (FDA) has decided to overhaul its approval system for generic drugs after mistakenly approving a generic that did not perform as well as its name-brand counterpart. ...
Continue reading "FDA Cracks Down on Generics after Wellbutrin Debacle" »
Posted on Nov 8, 2012 By Arnold & Itkin LLP
In a recent report, the Food and Drug Administration (FDA) suggests that their prior analysis of the blood-thinning medication, Pradaxa was flawed. The FDA's initial report of Pradaxa stated that, ...
Continue reading "Pradaxa Poses Increased Risk of Bleeding" »
Posted on Nov 8, 2012 By Arnold & Itkin LLP
A federal jury found drug manufacturer Novartis liable for a jawbone injury in a woman who took their cancer drug Zometa. She was awarded $10.45 million. The verdict is the second-largest Zometa ...
Continue reading "Jury Award of $10 million in Zometa Injury Case" »
Posted on Nov 2, 2012 By Arnold & Itkin, LLP
On October 2, a federal court in Virginia approved drug manufacturer Abbott Laboratories' $1.5 Billion settlement with the federal government to settle allegations that the company illegally ...
Continue reading "Abbott Laboratories Reaches $1.5 Billion Depakote Settlement" »
Posted on Nov 2, 2012 By Arnold & Itkin LLP
Johnson & Johnson has recalled more than 157,000 surgical stapler devices used in hemorrhoid treatment procedures because potential malfunctions pose a serious safety risk to patients. The Food ...
Continue reading "Johnson & Johnson Recalls Surgical Stapler" »
Posted on Nov 1, 2012 By Arnold & Itkin, LLP
A new report published in Consumer Reports Magazine has recommended against using the Type 2 diabetes medication Actos unless all other treatment options fail. According to the report, metformin and ...
Continue reading "Actos Should be Last Resort Drug, Report Says" »
Posted on Nov 1, 2012 By Arnold & Itkin, LLP
A new study published in BMJ online has revealed that elderly patients who are treated with anti-anxiety medications like Xanax, which contain benzodiazepines, are 50% more likely to develop dementia ...
Continue reading "Anxiety Medications Increase Risk of Dementia" »
Posted on Oct 31, 2012 By Arnold & Itkin, LLP
A new study published in the journal Frontiers in Evolutionary Psychology has found that the risks associated with antidepressants outweigh the benefits they may produce. As a result of the findings, ...
Continue reading "Antidepressants Do More Harm than Good" »
Posted on Oct 31, 2012 By Arnold & Itkin LLP
Boehringer Ingelheim Pharmaceuticals Inc. has agreed to pay $95 million to the U.S. government to settle charges that it illegally marketed drugs for unapproved uses. According to the Department of ...
Continue reading "Boehringer to Pay $95 Million to Settle Illegal Marketing Charges" »
Posted on Oct 30, 2012 By Arnold & Itkin, LLP
In the last three years, six of the major manufacturers of sterile injectable medications have received warnings about major health and safety violations at their plants from the Food and Drug ...
Continue reading "Drug Manufacturers Allow Many Safety Lapses" »
Posted on Oct 30, 2012 By Arnold & Itkin, LLP
Compound medicines are drugs specially manufactured by pharmacies as opposed to larger scale drug makers. These drugs have come to the forefront of public attention recently as one compound ...
Continue reading "Are Compounded Medicines Safe?" »
Posted on Oct 29, 2012 By Arnold & Itkin, LLP
Drug manufacturer Johnson & Johnson has agreed to settle five lawsuits that claimed that their anti-psychotic drug Risperdal caused breast-growth in teenage boys. Johnson & Johnson has already ...
Continue reading "Johnson & Johnson Settles Risperdal Male Breast Growth Suits" »
Posted on Oct 29, 2012 By Arnold & Itkin, LLP
On October 3, the Food and Drug Administration (FDA) asked Teva Pharmaceuticals to withdraw its drug Budeprion XL 300 after testing showed the drug did not properly release its key ingredient. The ...
Continue reading "Government Approved Defective Generic Drug" »
Posted on Oct 28, 2012 By Arnold & Itkin, LLP
The first case over injuries caused by drug manufacturer Johnson & Johnson's Risperdal is currently pending in Philadelphia, and new evidence is emerging that the company knew of, and hid, ...
Continue reading "New Evidence that J&J hid Risperdal Side Effects" »
Posted on Oct 28, 2012 By Arnold & Itkin, LLP
A rare, non-contagious form of meningitis has claimed 12 lives in five states after the New England Compounding Center (NECC) produced a contaminated steroid injection that may have been given to as ...
Continue reading "Meningitis Case in Florida Raises Outbreak Death Toll to 12" »
Posted on Oct 27, 2012 By Arnold & Itkin, LLP
A recent study published in the Archives of General Psychiatry has discovered a potential link between the prenatal use of selective serotonin inhibitor (SSRI) antidepressants and small fetal head ...
Continue reading "SSRIs Linked to Problems with Fetal Head Development" »
Posted on Oct 26, 2012 By Arnold & Itkin, LLP
Pfizer Inc. has reached a confidential settlement with the wife of a man who killed himself after taking the drug maker's anti-smoking medication, Chantix. Mark Alan Whitely's widow sued ...
Continue reading "Settlement Reached in Chantix Suicide Case" »
248 results found. Viewing page 1 of 10.
Go to page